Evidence map›Paper›PMID 36820302›Full record

ArticleMolecular therapy oncolytics2023

A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics.

Sihao Zhu, Ziyuan Li, Dongye Zheng, Yue Yu, Jing Xiang, Xiao Ma, Dongqing Xu, Jiajun Qiu, Ziyu Yang, Zhiyi Wang and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Sihao ZhuDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Ziyuan LiDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Dongye ZhengDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Yue YuBeijing National Laboratory for Molecular Sciences (BNLMS), Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Jing XiangDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Xiao MaResearch Group Signal Transduction, Department of Psychiatry, Ludwig Maximilian University of Munich, Nussbaumstr.7, 80336 Munich, Germany.
Dongqing XuDepartment of Pediatric Hematology/Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Jiajun QiuDepartment of Otolaryngology Head and Neck Surgery, the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Ziyu YangCollege of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.
Zhiyi WangSchool of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, China.
Jun LiLaboratory Animal Center, Peking University, Beijing 100871, China.
Hongfang SunDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Weiqiang ChenInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, Gansu Province, China.
Xiangxi MengKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Yanye LuDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Qiushi RenDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Peking University · CNShanghai Jiao Tong University · CNChinese Academy of Sciences · CNLudwig-Maximilians-Universität München · DEShenzhen University · CNSouth China University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endogenous microRNAs (miRNA) in tumors are currently under exhaustive investigation as potential therapeutic agents for cancer treatment. Nevertheless, RNase degradation, inefficient and untargeted delivery, limited biological effect, and currently unclear side effects remain unsettled issues that frustrate clinical application. To address this, a versatile targeted delivery system for multiple therapeutic and diagnostic agents should be adapted for miRNA. In this study, we developed membrane-coated PLGA-b-PEG DC-chol nanoparticles (m-PPDCNPs) co-encapsulating doxorubicin (Dox) and miRNA-190-Cy7. Such a system showed low biotoxicity, high loading efficiency, and superior targeting ability. Systematic delivery of m-PPDCNPs in mouse models showed exceptionally specific tumor accumulation. Sustained release of miR-190 inhibited tumor angiogenesis, tumor growth, and migration by regulating a large group of angiogenic effectors. Moreover, m-PPDCNPs also enhanced the sensitivity of Dox by suppressing TGF-β signal in colorectal cancer cell lines and mouse models. Together, our results demonstrate a stimulating and promising m-PPDCNPs nanoplatform for colorectal cancer theranostics.

Indexed as

angiogenesis inhibitionhomologous targetingmicroRNA deliverymicroRNA therapeuticstheranostics

Identifiers

PMID36820302
PMCPMC9937835
OpenAlexW4311170287

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.